Park Avenue Securities LLC Boosts Stock Position in Enovis Corporation $ENOV

Park Avenue Securities LLC increased its stake in Enovis Corporation (NYSE:ENOV) by 10.2% during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 13,474 shares of the company’s stock after buying an additional 1,247 shares during the period. Park Avenue Securities LLC’s holdings in Enovis were worth $423,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Farther Finance Advisors LLC lifted its position in Enovis by 266.7% in the 1st quarter. Farther Finance Advisors LLC now owns 737 shares of the company’s stock valued at $27,000 after acquiring an additional 536 shares in the last quarter. GAMMA Investing LLC lifted its position in Enovis by 144.8% in the 1st quarter. GAMMA Investing LLC now owns 1,170 shares of the company’s stock valued at $45,000 after acquiring an additional 692 shares in the last quarter. DekaBank Deutsche Girozentrale lifted its position in Enovis by 57.7% in the 1st quarter. DekaBank Deutsche Girozentrale now owns 1,981 shares of the company’s stock valued at $74,000 after acquiring an additional 725 shares in the last quarter. Cullen Frost Bankers Inc. bought a new position in Enovis in the 1st quarter valued at approximately $198,000. Finally, McIlrath & Eck LLC lifted its position in Enovis by 52.2% in the 1st quarter. McIlrath & Eck LLC now owns 5,274 shares of the company’s stock valued at $202,000 after acquiring an additional 1,808 shares in the last quarter. 98.45% of the stock is owned by institutional investors.

Enovis Price Performance

NYSE ENOV opened at $30.19 on Tuesday. The business’s fifty day moving average price is $29.82 and its 200-day moving average price is $32.26. The stock has a market capitalization of $1.73 billion, a price-to-earnings ratio of -2.12 and a beta of 1.68. The company has a debt-to-equity ratio of 0.53, a current ratio of 2.25 and a quick ratio of 1.15. Enovis Corporation has a 1-year low of $25.47 and a 1-year high of $49.83.

Enovis (NYSE:ENOV) last posted its quarterly earnings data on Thursday, August 7th. The company reported $0.79 EPS for the quarter, topping the consensus estimate of $0.74 by $0.05. The firm had revenue of $564.50 million during the quarter, compared to analyst estimates of $555.80 million. Enovis had a positive return on equity of 6.78% and a negative net margin of 37.80%.Enovis’s revenue was up 7.5% on a year-over-year basis. During the same period in the prior year, the business posted $0.62 EPS. Enovis has set its FY 2025 guidance at 3.050-3.200 EPS. On average, equities analysts predict that Enovis Corporation will post 2.79 earnings per share for the current year.

Wall Street Analyst Weigh In

ENOV has been the topic of several analyst reports. Wells Fargo & Company lowered their price objective on Enovis from $48.00 to $41.00 and set an “overweight” rating on the stock in a research report on Friday, August 8th. Evercore ISI lowered their price objective on Enovis from $48.00 to $46.00 and set an “outperform” rating on the stock in a research report on Tuesday, July 8th. Canaccord Genuity Group lowered their price objective on Enovis from $70.00 to $58.00 and set a “buy” rating on the stock in a research report on Friday, August 8th. UBS Group lowered their price target on Enovis from $65.00 to $57.00 and set a “buy” rating on the stock in a report on Friday, August 8th. Finally, Needham & Company LLC lowered their price target on Enovis from $57.00 to $49.00 and set a “buy” rating on the stock in a report on Thursday, August 7th. Six equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $51.00.

Insider Transactions at Enovis

In related news, CEO Damien Mcdonald acquired 6,457 shares of Enovis stock in a transaction dated Thursday, September 11th. The stock was purchased at an average cost of $30.97 per share, for a total transaction of $199,973.29. Following the purchase, the chief executive officer directly owned 102,753 shares of the company’s stock, valued at approximately $3,182,260.41. This trade represents a 6.71% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Also, SVP Bradley J. Tandy acquired 3,200 shares of Enovis stock in a transaction dated Friday, August 22nd. The stock was bought at an average price of $31.41 per share, with a total value of $100,512.00. Following the completion of the purchase, the senior vice president directly owned 43,515 shares in the company, valued at $1,366,806.15. This represents a 7.94% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders purchased 12,157 shares of company stock worth $374,760 in the last three months. Corporate insiders own 2.70% of the company’s stock.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.